<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158197</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-17407-1</org_study_id>
    <secondary_id>R01DA017407</secondary_id>
    <secondary_id>R01-17407-1</secondary_id>
    <nct_id>NCT00158197</nct_id>
  </id_info>
  <brief_title>Long-term Behavior Change - 1</brief_title>
  <official_title>Behavior Change: Reinforcement Schedule Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Friends Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Friends Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if different reinforcement procedures (i.e.,
      schedules) produce different patterns of long-term abstinence from methamphetamine. We
      anticipate that the three contingency management conditions will promote longer periods of
      abstinence in the year following treatment relative to the standard control group.
      Furthermore, we predict that the intermittent reinforcement procedures will produce longer
      periods of continued abstinence (i.e., long-term behavior change) in the year following
      treatment than the continuous reinforcement procedure. Finally, we predict that the
      intermittent unpredictable schedule will produce longer lasting behavior change than the
      intermittent predictable schedule. Methamphetamine use will be measured using urine
      toxicology and self-report of methamphetamine use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Briefly the four study conditions are: (1) standard treatment which consists of 16 weeks of
      psychosocial treatment, (2) continuous contingency management which consists of 16 weeks of
      psychosocial treatment with a contingency management procedure in effect during the first
      twelve weeks in which vouchers are made available after each provision of a
      methamphetamine-negative urine test, (3) intermittent predictable contingency management
      which consists of 16 weeks of psychosocial treatment with a contingency management procedure
      in effect during the first twelve weeks in which vouchers are available after the provision
      of every three consecutive methamphetamine-negative urine samples, and (4) intermittent
      unpredictable contingency management which consists of 16 weeks of psychosocial treatment
      with a contingency management procedure in effect during the first twelve weeks in which
      vouchers are available on one day each week (randomly selected after the first week) for the
      provision of methamphetamine-negative urine samples provided all urine samples since delivery
      of the last reinforcer were also methamphetamine negative.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methamphetamine Use During Intervention</measure>
    <time_frame>3x/week for 16 weeks</time_frame>
    <description>Drug use measured by urine toxicology conducted by on site Enzyme-multiplied immunoassay technique (EMIT) assay over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methamphetamine Use, Measured by Number of Consecutive Days of Abstinence</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Drug use measured by urine toxicology conducted by on site EMIT assay and added up to obtain how many days of consecutive abstinence were observed for each individual</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methamphetamine Use, Follow-Up</measure>
    <time_frame>1x/month for 4 months</time_frame>
    <description>Drug use measured by urine toxicology conducted by on site EMIT assay over time</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Amphetamine-related Disorders</condition>
  <arm_group>
    <arm_group_label>continuous voucher schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, &amp; F) for twelve weeks and will complete study-related measures one time per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermittent predictable schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, &amp; F) for twelve weeks and will complete study-related measures one time per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermittent unpredictable schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, &amp; F for 12 wks and complete measures 1x/wk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, &amp; F) for twelve weeks and will complete study-related measures one time per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>contingency management voucher</intervention_name>
    <description>participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
    <arm_group_label>continuous voucher schedule</arm_group_label>
    <arm_group_label>intermittent predictable schedule</arm_group_label>
    <arm_group_label>intermittent unpredictable schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for
             methamphetamine dependence

          -  Willing and able to comply with study procedures

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Have a medical condition that, in the study Principal Investigator (PI's) judgment,
             might interfere with safe study participation

          -  Have a recent (past 30 days) history of suicide attempts and/or current serious
             suicidal intention or plan as assessed by the Beck Depression Inventory (BDI)

          -  Have a history of violent criminal behavior or be on parole

          -  Any other circumstances that, in the opinion of the PI, would interfere with safe
             study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Roll, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Roll JM, Chudzynski J, Cameron JM, Howell DN, McPherson S. Duration effects in contingency management treatment of methamphetamine disorders. Addict Behav. 2013 Sep;38(9):2455-62. doi: 10.1016/j.addbeh.2013.03.018. Epub 2013 Apr 3.</citation>
    <PMID>23708468</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>May 30, 2013</results_first_submitted>
  <results_first_submitted_qc>June 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>Amphetamine-Related Disorders</keyword>
  <keyword>Behavior Therapy</keyword>
  <keyword>Contingency management</keyword>
  <keyword>Drug Counseling</keyword>
  <keyword>health behaviors</keyword>
  <keyword>methamphetamine</keyword>
  <keyword>sexual risk behaviors</keyword>
  <keyword>substance dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment and enrollment began in January 2005 and ended . Individuals were recruited from the community via radio and newspaper ads, flyers, and word of mouth.</recruitment_details>
      <pre_assignment_details>The main reasons individuals were excluded from the trial prior to group assignment was not meeting inclusion criteria and discontinuing treatment prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intermittent Predictable Schedule</title>
          <description>Those in the intermittent predictable condition earned a voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition received $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There were no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, resulted in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
        </group>
        <group group_id="P2">
          <title>Continuous Schedule</title>
          <description>Those in the continuous condition received a voucher each time they tested negative for methamphetamine. The initial voucher value was $2.50. Each consecutive instance of abstinence increased the magnitude of the voucher by $1.50. Three consecutive abstinences resulted in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, resulted in a reset in the voucher magnitude back to its original level from whence the progression could begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
        </group>
        <group group_id="P3">
          <title>Intermittent Unpredictable Schedule</title>
          <description>Participants in the unpredictable intermittent condition earned vouchers of the same magnitude as those in the predictable intermittent condition and at approximately the same rate (i.e., $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second week of methamphetamine-negative urines, etc). More specifically, participants in this group received a voucher for $22.00 following their first three methamphetamine-negative urine tests. Following that they were eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. This date was randomly determined and they did not know in advance what day it was.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
        </group>
        <group group_id="P4">
          <title>Standard</title>
          <description>Participants assigned to the standard condition did not receive vouchers for the provision of clean urines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intermittent Predictable Schedule</title>
          <description>Those in the intermittent predictable condition will earn a voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency managment voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
        </group>
        <group group_id="B2">
          <title>Continuous Voucher Schedule</title>
          <description>Those in the continuous condition will receive a voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency managment voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
        </group>
        <group group_id="B3">
          <title>Intermittent Unpredictable Schedule</title>
          <description>Those in the intermittent unpredictable condition will be eligible to receive a voucher on one day a week. This date will be randomly determined and they will not know in advance what day it will be. Participants in this group will receive a voucher following their first three methamphetamine-negative urine tests. Following that they will be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test.
contingency managment voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
        </group>
        <group group_id="B4">
          <title>Standard</title>
          <description>Participants assigned to the standard condition will not receive vouchers for the provision of clean urines.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="8.2"/>
                    <measurement group_id="B2" value="32.5" spread="10"/>
                    <measurement group_id="B3" value="30.3" spread="10.9"/>
                    <measurement group_id="B4" value="24.8" spread="10.1"/>
                    <measurement group_id="B5" value="32" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methamphetamine Use During Intervention</title>
        <description>Drug use measured by urine toxicology conducted by on site Enzyme-multiplied immunoassay technique (EMIT) assay over time.</description>
        <time_frame>3x/week for 16 weeks</time_frame>
        <population>All individuals randomized were included in the analysis (i.e., intention to treat).</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Predictable Schedule</title>
            <description>Those in the intermittent predictable condition will earn a voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O2">
            <title>Continuous Voucher Schedule</title>
            <description>Those in the continuous condition will receive a voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O3">
            <title>Intermittent Unpredictable Schedule</title>
            <description>Those in the intermittent unpredictable condition will be eligible to receive a voucher on one day a week. This date will be randomly determined and they will not know in advance what day it will be. Participants in this group will receive a voucher following their first three methamphetamine-negative urine tests. Following that they will be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O4">
            <title>Standard</title>
            <description>Participants assigned to the standard condition will not receive vouchers for the provision of clean urines.</description>
          </group>
        </group_list>
        <measure>
          <title>Methamphetamine Use During Intervention</title>
          <description>Drug use measured by urine toxicology conducted by on site Enzyme-multiplied immunoassay technique (EMIT) assay over time.</description>
          <population>All individuals randomized were included in the analysis (i.e., intention to treat).</population>
          <units>percentage of negative urine samples</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Urine samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1536"/>
                <count group_id="O2" value="1440"/>
                <count group_id="O3" value="1344"/>
                <count group_id="O4" value="1392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.17"/>
                    <measurement group_id="O2" value="60.35"/>
                    <measurement group_id="O3" value="57.74"/>
                    <measurement group_id="O4" value="42.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Generalized estimating equations</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.98</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Value represents the odds of submitting a methamphetamine negative urine sample in the treatment group (1 of 3) compared to the standard care group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Generalized estimating equations</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.40</param_value>
            <estimate_desc>Value represents the odds of submitting a methamphetamine negative urine sample in the treatment group (1 of 3) compared to the standard care group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Generalized estimating equations</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <estimate_desc>Value represents the odds of submitting a methamphetamine negative urine sample in the treatment group (1 of 3) compared to the standard care group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Methamphetamine Use, Measured by Number of Consecutive Days of Abstinence</title>
        <description>Drug use measured by urine toxicology conducted by on site EMIT assay and added up to obtain how many days of consecutive abstinence were observed for each individual</description>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Predictable Schedule</title>
            <description>Those in the intermittent predictable condition will earn a voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O2">
            <title>Continuous Voucher Schedule</title>
            <description>Those in the continuous condition will receive a voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O3">
            <title>Intermittent Unpredictable Schedule</title>
            <description>Those in the intermittent unpredictable condition will be eligible to receive a voucher on one day a week. This date will be randomly determined and they will not know in advance what day it will be. Participants in this group will receive a voucher following their first three methamphetamine-negative urine tests. Following that they will be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O4">
            <title>Standard</title>
            <description>Participants assigned to the standard condition will not receive vouchers for the provision of clean urines.</description>
          </group>
        </group_list>
        <measure>
          <title>Methamphetamine Use, Measured by Number of Consecutive Days of Abstinence</title>
          <description>Drug use measured by urine toxicology conducted by on site EMIT assay and added up to obtain how many days of consecutive abstinence were observed for each individual</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.42" spread="15.36"/>
                    <measurement group_id="O2" value="22.7" spread="17.60"/>
                    <measurement group_id="O3" value="20.32" spread="18.64"/>
                    <measurement group_id="O4" value="11.10" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>Yes, the a priori plan to handle post hoc multiple comparisons was to use the method of Bonferroni adjustment. Thus, the new alpha level for these comparisons was &lt;0.0125.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Methamphetamine Use, Follow-Up</title>
        <description>Drug use measured by urine toxicology conducted by on site EMIT assay over time</description>
        <time_frame>1x/month for 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Predictable Schedule</title>
            <description>Those in the intermittent predictable condition will earn a voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O2">
            <title>Continuous Voucher Schedule</title>
            <description>Those in the continuous condition will receive a voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O3">
            <title>Intermittent Unpredictable Schedule</title>
            <description>Those in the intermittent unpredictable condition will be eligible to receive a voucher on one day a week. This date will be randomly determined and they will not know in advance what day it will be. Participants in this group will receive a voucher following their first three methamphetamine-negative urine tests. Following that they will be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test.
contingency management voucher : participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.</description>
          </group>
          <group group_id="O4">
            <title>Standard</title>
            <description>Participants assigned to the standard condition will not receive vouchers for the provision of clean urines.</description>
          </group>
        </group_list>
        <measure>
          <title>Methamphetamine Use, Follow-Up</title>
          <description>Drug use measured by urine toxicology conducted by on site EMIT assay over time</description>
          <units>percentage of negative urine samples</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Urine samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.79"/>
                    <measurement group_id="O2" value="88.89"/>
                    <measurement group_id="O3" value="88.62"/>
                    <measurement group_id="O4" value="87.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>We used GEE to investigate change in methamphetamine abstinence (i.e., provision of a negative methamphetamine UA) during the follow-up period.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Generalized estimating equations</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>We used GEE to investigate change in methamphetamine abstinence (i.e., provision of a negative methamphetamine UA) during the follow-up period.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Generalized estimating equations</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>We used GEE to investigate change in methamphetamine abstinence (i.e., provision of a negative methamphetamine UA) during the follow-up period.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Generalized estimating equations</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data were collected at each study and follow-up visit, for 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continuous Voucher Schedule</title>
          <description>Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, &amp; F) for twelve weeks and will complete study-related measures one time per week.</description>
        </group>
        <group group_id="E2">
          <title>Intermittent Predictable Schedule</title>
          <description>Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, &amp; F) for twelve weeks and will complete study-related measures one time per week.</description>
        </group>
        <group group_id="E3">
          <title>Intermittent Unpredictable Schedule</title>
          <description>Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, &amp; F for 12 wks and complete measures 1x/wk.</description>
        </group>
        <group group_id="E4">
          <title>Standard</title>
          <description>Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, &amp; F) for twelve weeks and will complete study-related measures one time per week.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <description>Ct hospitalized to monitor chest pain and tightness. Prescribed heart and pain medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus, Type II</sub_title>
                <description>Client sought medical attention due to increased thirst and frequency in urination. Client was hospitalized overnight to monitor glucose levels. Client was diagnosed with Diabetes Mellitus, Type II.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>High glucose levels</sub_title>
                <description>Client sought medical attention for frequent urination and thirst. Client admitted to hospital for high glucose levels and was given insulin for stabilization.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>breathing difficulty</sub_title>
                <description>Client sought medical attention as he was having difficulty breathing hearing properly. Client diagnosed with infection that progressed due to high blood sugar levels.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>Ct hospitalized for difficulty breathing and edema, diagnosed with pneumonia. Ct was hospitalized and received fluids and antibiotics intravenously along with oxygen and breathing treatments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Client sought medical attention due to pains in chest and difficulty breathing. Client was diagnosed with pneumonia.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>back and lung injury</sub_title>
                <description>Ct hospitalized for stab wounds in the face and back. Ct underwent surgery for back and lung injuries. Ct was released with prescriptions for painkillers, iron and glucose.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>slipped vertebral disk</sub_title>
                <description>Pain and stiffness in neck.Diagnosed with a slipped vertebral disk and underwent surgery to correct it. Ct was prescribed painkillers and assigned physical therapy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nerve pain</sub_title>
                <description>Client underwent surgery to alleviate compression of the seventh cranial nerve.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>child birth</sub_title>
                <description>Ct reported seeking medical attention due to labor pains. Ct gave birth to health child.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye surgery</sub_title>
                <description>Ct reported undergoing surgery on left eye to remove cataract. Ct was released the same day with a prescription for steroid eye drops.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>eye lesions</sub_title>
                <description>Client sought medical attention for eye lesions. Ct was diagnosed with Herpes of the eyes, and was prescribed antibiotic ointments and antiviral drops.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>abscesses on legs</sub_title>
                <description>Ct reported seeking medical attention for abscesses on legs. Ct underwent minor surgery to remove boils, and was released the same day.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>rash and blisters</sub_title>
                <description>Ct sought medical attention for rashes and blisters on both legs, which spread throughout body. Ct prescribed broad-spectrum antibiotics, antivirals, and topical ointments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>Ct reported receiving medical attention for a high fever. Ct was diagnosed with a kidney infection, prescribed an antibiotic, and released the same day.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>decayed teeth</sub_title>
                <description>Client reported receiving oral surgery for decayed teeth. Ct was released the same day with antibiotics.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>pain and swelling</sub_title>
                <description>Client sought medical attention for pain and swelling in testicular area. Ct was diagnosed with build-up of fluid. Client to schedule procedure for drainage.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>tooth pain</sub_title>
                <description>Ct reported seeking medical attention for tooth pain. Ct told to schedule tooth extractions.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>leg injury</sub_title>
                <description>Ct sought medical attention due to a leg injury as a result of falling while hiking. Ct received 21 stitches in left leg, and was prescribed antibiotics.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>broken thumb</sub_title>
                <description>Client reported seeking medical attention for broken thumb. Splint was placed on clients thumb</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>lower back pain</sub_title>
                <description>Ct sought medical attention for lower back pain. Ct was diagnosed with pinched sciatic nerve, herniated disc, low back muscle strain, and lumbar muscle strain.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joy Chudzynski</name_or_title>
      <organization>Friends Research Institute</organization>
      <phone>323-333-8122</phone>
      <email>joychud@ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

